Engineered nanomedicine for myeloma and bone microenvironment targeting

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 28, 2014, Pages 10287-10292

  Swami, Archana ^a   Reagan, Michaela R ^b   Basto, Pamela ^c   Mishima, Yuji ^b   Kamaly, Nazila ^a   Glavey, Siobhan ^b   Zhang, Sufeng ^c   Moschetta, Michele ^b   Seevaratnam, Dushanth ^a   Zhang, Yong ^b   Liu, Jinhe ^a   Memarzadeh, Masoumeh ^b   Wu, Jun ^a   Manier, Salomon ^b   Shi, Jinjun ^a   Bertrand, Nicolas ^c   Lu, Zhi Ning ^b   Nagano, Kenichi ^d   Baron, Roland ^d   Sacco, Antonio ^b   Roccaro, Aldo M ^b   Farokhzad, Omid C ^a,e   Ghobrial, Irene M ^b   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alendronate PLGA PEG; Bisphosphonate; Bone metastasis; Targeting nanomedicine

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; HYDROXYAPATITE; MACROGOL; NANOPARTICLE; POLYGLACTIN; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BONE; BONE MASS; BONE STRENGTH; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG RETENTION; DRUG TARGETING; EX VIVO STUDY; FLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NANOENCAPSULATION; NANOENGINEERING; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SYNTHESIS; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ALENDRONATE-PLGA-PEG; BISPHOSPHONATE; BONE METASTASIS; TARGETING NANOMEDICINE;

ALENDRONATE; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HETEROGRAFTS; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; PYRAZINES; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904330291     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401337111     Document Type: Article

References (25)

1. Roodman GD (2009) Pathogenesis of myeloma bone disease. Leukemia 23(3):435-441.
2. Reagan MR, Ghobrial IM (2012) Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clin Cancer Res 18(2):342-349.
3. Coleman RE (2001) Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165-176.
4. Garrett IR, et al. (2003) Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111(11):1771-1782. (Pubitemid 38057757)
5. Ozaki S, et al. (2007) Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 86(2):180-185. (Pubitemid 47425199)
6. Giuliani N, et al. (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110(1):334-338. (Pubitemid 47026851)
7. Heider U, et al. (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77(3):233-238. (Pubitemid 44181386)
8. Zangari M, et al. (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131(1):71-73. (Pubitemid 43899710)
9. Terpos E, et al. (2010) Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 21(7):1561-1562.
10. Hrkach J, et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 4(128):128ra39.
11. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev 41(7):2971-3010.
12. Swami A, et al. (2012) Multifunctional Nanoparticles for Drug Delivery Applications, eds Svenson S, Prud'homme RK (Springer, Boston), pp 9-29.
13. Zhang X-Q, et al. (2012) Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 64(13):1363-1384.
14. Zhang S, Gangal G, Uludaǧ H (2007) "Magic bullets" for bone diseases: Progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 36(3):507-531.
15. Sayed D, Al-Sadoon MK, Badr G (2012) Silica nanoparticles sensitize human multiple myeloma cells to snake (Walterinnesia aegyptia) venom-induced apoptosis and growth arrest. Oxid Med Cell Longev 2012:386286.
16. Ravindran J, et al. (2010) Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol 79(11):1640-1647.
17. Sou K, Oyajobi B, Goins B, Phillips WT, Tsuchida E (2009) Characterization and cytotoxicity of self-organized assemblies of curcumin and amphiphatic poly(ethylene glycol). J Biomed Nanotechnol 5(2):202-208.
18. Taylor CA, et al. (2012) Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-κB activity and tumor growth in murine models of multiple myeloma. Mol Ther 20(7):1305-1314.
19. 4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice. Int J Nanomedicine 8:1439-1449.
20. Maillard S, et al. (2005) Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol 94(1-3):111-121. (Pubitemid 40614524)
21. Cirstea D, et al. (2010) Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 9(4):963-975.
22. Azab AK, et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113(18):4341-4351.
23. Pridgen EM, et al. (2013) Transepithelial transport of fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 5(213):213ra167.
24. Leleu X, et al. (2007) The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 110(13):4417-4426. (Pubitemid 351377808)
25. Dempster DW, et al. (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2-17.